A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC

By afschroeder • June 15, 2025

Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, Pons-Tostivint E, Pérol M, Felip E, Sugawara S, Hayashi H, Cho BC, Blumenschein G Jr, Shum E, Lee JS, Heist RS, Cornelissen R, Chang WC, Kowalski D, Zebger-Gong H, Chargualaf M, Gu W, Lan L, Howarth P, Joseph R, Okamoto I. A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC. J Thorac Oncol. 2025 Jun 12:S1556-0864(25)00761-0. doi: 10.1016/j.jtho.2025.06.002. Epub ahead of print. PMID: 40516821.

Tags: Antibody–drug conjugate, Datopotamab deruxtecan, EGFR mutation, Hematology/Oncology, Non-small cell lung cancer, Pooled analysis, Publications

Related Posts

Asia Pacific Gastroesophageal Cancer Congress (APGCC) 2024 consensus statement on stage 2 and 3 locally advanced gastric and Siewert 3 junctional adenocarcinoma

Masuda Y, Fong KL, Yeo D, Yeo C, Chue KM, Araba SB, Lim CW, Yeung B, Lee J, Lin J, Chia C, Ng M, Ng[...]

Answering real-world clinical questions using large language model, retrieval-augmented generation, and agentic systems

Low YS, Jackson ML, Hyde RJ, Brown RE, Sanghavi NM, Baldwin JD, Pike CW, Muralidharan J, Hui G, Alexander N, Hassan H, Nene RV, Pike[...]

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

Zeidner JF, Lin TL, Welkie RL, Curran E, Koenig K, Stock W, Madanat YF, Swords R, Baer MR, Blum W, Stein EM, Olin RL, Schiller[...]